casein-hydrolysate and Weight-Gain

A masked, randomized, parallel growth study was conducted in infants fed an amino acid-based formula (AF) or an extensively hydrolyzed casein-based formula (HF). Infants were enrolled between 0 and 9 days and studied to 112 days of age. Growth, formula intake, stool patterns, and serum albumin concentrations were assessed. There were no significant differences between groups in weight, length, or head circumference, gains in weight or length, or study formula intake. The number of stools parents rated as being formed, and the mean daily number of stools were greater in the HF than in the AF group at 14 and 28 days of age. Mean serum albumin concentrations were not significantly different between groups and were within the normal range. This study demonstrates that AF supports normal growth of infants comparable to that of infants fed HF during the critical first 4 months of life.

Topics: Amino Acids; Caseins; Double-Blind Method; Eating; Feces; Growth; Humans; Infant; Infant Equipment; Infant, Newborn; Serum Albumin; Weight Gain

Previous research has shown that administering carbohydrates to late-term embryos increases chick hatching weight and liver glycogen content and that supplementing broiler chicks from young hens at day of hatch with subcutaneously injected hydrolyzed casein and thiamine enhances their early performance. It was hypothesized that other practical and readily available gluconeogenic energy sources, including hydrolyzed casein, may similarly be given to hatchlings from immature breeder hens to increase the availability of liver glycogen reserves and augment growth. In addition to physiological saline (sham) and hydrolyzed casein treatments, 2 other treatments containing practical gluconeogenic energy sources (chicken egg crude albumin or albumin hydrolysate) were tested in the current study using hatchlings that were subsequently provided adequate brooding and nutrition. Added biotin was included in the crude albumin treatment. There were no treatment effects on mortality, BW gain, feed or water consumption, feed conversion, body temperature, hematocrit, plasma refractive index, relative liver weight, or liver glycogen content at any of the ages or age intervals examined through d 16 posthatch. These results suggest that under proper brooding conditions and timely feed provision, growth is not facilitated by injected casein hydrolysate, chicken egg crude albumin, or chicken egg albumin hydrolysate during the early transition from fat to carbohydrate-based nutrient uptake in posthatch chicks from young breeder hens.

Topics: Albumins; Animals; Caseins; Chickens; Female; Gluconeogenesis; Injections, Subcutaneous; Liver; Liver Glycogen; Male; Organ Size; Thiamine; Vitamin B Complex; Weight Gain

Obesity frequently associates with the development of non-alcoholic fatty liver disease (NAFLD) and atherosclerosis. Chronic inflammation in white adipose tissue (WAT) seems to be an important driver of these manifestations.. This study investigated a combination of an extensively hydrolyzed casein (eHC), docosahexaenoic acid (DHA), arachidonic acid (ARA), and Lactobacillus Rhamnosus GG (LGG) (together referred to as nutritional ingredients, NI) on the development of obesity, metabolic risk factors, WAT inflammation, NAFLD and atherosclerosis in high-fat diet-fed LDLr-/-.Leiden mice, a model that mimics disease development in humans.. LDLr-/-.Leiden male mice (n = 15/group) received a high-fat diet (HFD, 45 Kcal%) for 21 weeks with or without the NI (23.7% eHC, 0.083% DHA, 0.166% ARA; all w/w and 1x109 CFU LGG gavage 3 times/week). HFD and HFD+NI diets were isocaloric. A low fat diet (LFD, 10 Kcal%) was used for reference. Body weight, food intake and metabolic risk factors were assessed over time. At week 21, tissues were analyzed for WAT inflammation (crown-like structures), NAFLD and atherosclerosis. Effects of the individual NI components were explored in a follow-up experiment (n = 7/group).. When compared to HFD control, treatment with the NI strongly reduced body weight to levels of the LFD group, and significantly lowered (P<0.01) plasma insulin, cholesterol, triglycerides, leptin and serum amyloid A (P<0.01). NI also reduced WAT mass and inflammation. Strikingly, NI treatment significantly reduced macrovesicular steatosis, lobular inflammation and liver collagen (P<0.05), and attenuated atherosclerosis development (P<0.01). Of the individual components, the effects of eHC were most pronounced but could not explain the entire effects of the NI formulation.. A combination of eHC, ARA, DHA and LGG attenuates obesity and associated cardiometabolic diseases (NAFLD, atherosclerosis) in LDLr-/-.Leiden mice. The observed reduction of inflammation in adipose tissue and in the liver provides a rationale for these comprehensive health effects.

Topics: Adiposity; Animals; Atherosclerosis; Caseins; Diet, High-Fat; Male; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Receptors, LDL; Weight Gain

The objective of this multiple-dose toxicity study was to assess the toxicological potential of two tripeptides, L-valyl-L-prolyl-L-proline (VPP) and L-isoleucyl-L-prolyl-L-proline (IPP), when administered once daily for 91 consecutive days to rats. The test article, powdered casein hydrolysate (CH) known to contain 0.6% VPP plus IPP, was prepared using Aspergillus oryzae protease. Prior to administration to the rats by oral gavage, the test article was suspended in sterile water. Groups of 12 male and 12 female Charles River rats were administered once daily doses of 0, 40, 200, or 1000 mg of CH (0, 0.2, 1.2, or 6 mg VPP plus IPP/kg body weight [BW]). Antemortem evaluative parameters included gross observations of behavior and clinical signs; food consumption and body weight gains; ophthalmologic examinations; clinical pathology (hematology, clinical chemistry); and urinalysis. Postmortem parameters included determination of absolute and relative (to fasting body weight) organ weights and histopathological evaluation of approximately 50 organs and tissues from each animal. All rats survived until the scheduled termination of the study and no treatment-related clinical signs were observed. Food consumption was unaffected by administration of CH. All animals gained weight and there were no statistical differences between groups with respect to weight gains. There were no meaningful changes in hematological or coagulation parameters. Mid- and high-dose males (but not females) had slightly (< 2%) increased mean serum chloride concentrations, but because the difference was so small and it was observed in only one sex, the authors considered its association with CH administration to be doubtful. Urinalysis revealed the occasional presence of crystals, leukocytes, and epithelial cells in animals from all experimental groups. Similarly, ophthalmic changes (lenticular clouding) were observed in both control and dosed animals. Mean relative (to body weight) kidney weight was decreased by 8% in low-dose males and mean relative uterus weight was elevated 46% in low-dose females. Absolute organ weights were not affected. Only naturally occurring microscopic changes were observed in all groups and none could be attributed to CH administration. It was concluded that, under the conditions of these experiments, the maximally tolerated dose (MTD) and the no-observable-effect level (NOEL) for powdered CH administered once daily for 13 weeks was greater than 1000 mg/kg BW/d

Topics: Administration, Oral; Animals; Caseins; Cataract; Chlorides; Dose-Response Relationship, Drug; Eating; Female; Hematologic Tests; Kidney; Male; Oligopeptides; Organ Size; Powders; Rats; Rats, Sprague-Dawley; Sex Factors; Time Factors; Toxicity Tests; Urobilinogen; Uterus; Weight Gain